ZaLCitabine ZLC


If you want to support NGYX Non-Profit initiative by advertising on this WEB site Click Here!


Correlated Genos/Phenos Subsets.

ZaLCitabine / ZLC / R overview.

Remark: Some data relate to Subset#1 (Free) used as an example (1 out of 25). You can access an INFO file with Raw data to analyse and complete the picture. Click HERE.


If you want to catch the Subset#1  Dataset (or even more) Click HERE. 


I. G/Ps Content and Clades Prevalance.

II. Drug Resistance accross G/Ps.

NGYX I.C. Comment(s): Phenotypic results (various sources) almost perfectly fall within the test dynamic range. But here also the point is that (and this appears for many drugs) Drug Dilutions to generate IC50 values were to distant = often x4/x5. Switch to x2/x3 and adding 2-3 measurements would have been very beneficial to optimize sensitivity of the test.


III. Additional Remarks.

A. ZLC is rated at 5% on the NGYX I.C.Scale of Drug Resistance Interest (DRI). This means that each couple of G/P is valuable maximally for 0.05 Euros. If you want to know more about DRI Click HERE.


B. Combining subsets will impact the number of variables (mutations / clades) that NGIX I.C. classify as "ACCEPTED". T0 know more about this Click HERE.


NGYX I.C. details / Coordinates.

Company N°: BE 0537.471.159

Postal Adress:  NGYX I.C. (P. LECOCQ ),rue des Hausseurs 10, B-4550 Nandrin, BELGIUM. Email:  Info@NGYX.EU              Tel. / GSM: +32 498 532496 IBAN: BE63 7506 5746 0708 BIC: AXABBE22

Email  us: Click Here!